We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+104.41%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$326M
Cap. Flow
-$171M
Cap. Flow %
-10.24%
Top 10 Hldgs %
58.94%
Holding
43
New
12
Increased
5
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$80.5M
2
MGNX icon
MacroGenics
MGNX
+$70.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$70M
4
CGEN icon
Compugen
CGEN
+$55M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$52.9M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$128M
2
QURE icon
uniQure
QURE
+$58M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$54.1M
4
EPZM
Epizyme, Inc
EPZM
+$51.3M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$41M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
1
DELISTED
Mersana Therapeutics
MRSN
$138M 8.27%
+235,853
New +$80.5M
KPTI icon
2
Karyopharm Therapeutics
KPTI
$159M
$123M 7.37%
432,787
-45,926
-10% -$13.6M
MGNX icon
3
MacroGenics
MGNX
$240M
$113M 6.76%
+4,041,535
New +$70.2M
GNMK
4
DELISTED
GenMark Diagnostics, Inc
GNMK
$101M 6.08%
+6,894,481
New +$70M
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
$98.2M 5.88%
1,706,426
-591,353
-26% -$32.2M
AKBA icon
6
Akebia Therapeutics
AKBA
$362M
$95.5M 5.72%
7,031,283
-90,000
-1% -$931K
KDMN
7
DELISTED
Kadmon Holdings, Inc.
KDMN
$80.4M 4.82%
15,710,548
+101,600
+0.7% +$455K
CDNA icon
8
CareDx
CDNA
$1.97B
$79.1M 4.74%
2,232,612
-428,104
-16% -$12.2M
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$78.9M 4.73%
3,347,232
-85,000
-2% -$1.59M
ATRA icon
10
Atara Biotherapeutics
ATRA
$73.6M
$76.3M 4.57%
+209,529
New +$52.9M
AUPH icon
11
Aurinia Pharmaceuticals
AUPH
$1.93B
$75.1M 4.5%
4,621,325
-2,288,049
-33% -$36.6M
ASMB icon
12
Assembly Biosciences
ASMB
$516M
$74.1M 4.44%
264,628
– –
KNSA icon
13
Kiniksa Pharmaceuticals
KNSA
$6.1B
$72.4M 4.34%
2,843,384
+602,605
+27% +$12.6M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.64B
$68.3M 4.09%
425,716
-397,449
-48% -$54.1M
OMER icon
15
Omeros
OMER
$863M
$61.4M 3.68%
4,169,872
-310,000
-7% -$4.63M
CGEN icon
16
Compugen
CGEN
$220M
$61.2M 3.67%
+4,077,421
New +$55M
APRE icon
17
Aprea Therapeutics
APRE
$7.86M
$48.6M 2.91%
+62,609
New +$41.1M
APTO
18
DELISTED
Aptose Biosciences, Inc.
APTO
$44M 2.64%
15,489
+2,608
+20% +$8.41M
LMNL
19
DELISTED
Liminal BioSciences Inc. Common Shares
LMNL
$35.4M 2.12%
328,731
– –
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$23.7M 1.42%
4,650,565
+1,500,000
+48% +$6.25M
BLU
21
DELISTED
BELLUS Health Inc.
BLU
$19.8M 1.19%
1,922,503
+325,000
+20% +$3.29M
OVID icon
22
Ovid Therapeutics
OVID
$442M
$18.9M 1.14%
2,570,878
-10,000
-0.4% -$46.8K
STXS icon
23
Stereotaxis
STXS
$133M
$16.3M 0.98%
+3,658,537
New +$14.8M
HARP
24
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$14M 0.84%
+84,416
New +$13.2M
ATNM icon
25
Actinium Pharmaceuticals
ATNM
$26.3M
$13M 0.78%
+1,233,333
New +$9.34M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Consonance Capital Management held 43 positions worth $1.67B, up 24% from $1.34B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Consonance Capital Management withdrew a net $171M in Q2 2020, closing 11 positions and reducing 11 holdings. Its most notable exit was United Therapeutics, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Mersana Therapeutics worth $138M.

  • Consonance Capital Management's largest Q2 2020 buy was Mersana Therapeutics: 235,853 shares worth $138M.
  • Consonance Capital Management added most to Kiniksa Pharmaceuticals in Q2 2020, an estimated $12.6M increase.
  • Consonance Capital Management's biggest Q2 2020 reduction was uniQure, cutting an estimated $58M.
  • Consonance Capital Management fully exited United Therapeutics in Q2 2020, selling an estimated $128M.
  • Consonance Capital Management's ten largest holdings make up 59% of its $1.67B portfolio in Q2 2020.
  • Consonance Capital Management opened 12 new positions and closed 11 in Q2 2020.
  • Consonance Capital Management's portfolio value rose 24% quarter-over-quarter to $1.67B.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.